Drug Profile
Renal cancer vaccine - University of Tubingen
Latest Information Update: 25 Jan 2017
Price :
$50
*
At a glance
- Originator University of Tubingen
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Renal cancer
Most Recent Events
- 24 Jan 2017 Discontinued - Phase-I for Renal cancer in Germany (SC)
- 05 Jan 2001 Suspended-I for Renal cancer in Germany (SC)
- 19 Apr 1999 Phase-I clinical trials for Renal cancer in Germany (SC)